Oxford Nanopore signs CRISPR licence
20-09-2019
ERS extends CRISPR influence with two licensing deals
20-09-2018
Pacific Biosciences and Oxford Nanopore settle patent claims
09-05-2018
Xesai / iStockphoto.com
Amgen has invested £50 million ($66 million) in Oxford Nanopore Technologies, a UK company specialising in DNA/RNA sequencing technology.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Oxford Nanopore Technologies, Amgen, investment, gene sequencing, DNA, RNA
